Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease

Recruiting

Phase 1

Phase 2

Gene CorrectionGene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease

Sponsor:

Kamau Therapeutics

Code:

NCT04819841

Conditions

Sickle Cell Disease

Eligibility Criteria

Sex: All

Age: 12 - 40

Healthy Volunteers: Not accepted

Interventions

nula-cel Drug Product

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-07. This information was provided to ClinicalTrials.gov by Kamau Therapeutics on 2025-10-23.